HERCULES, CA — September 10, 2008 — Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced today the release of new software for Bio-Rad's Experion automated electrophoresis system, which enables fast and high resolution results for protein, RNA, and DNA separations. The new software optimizes these processes by providing easy access to the setup, running, and data analysis functions of the system.
An important feature of the software is its RNA quality indicator (RQI), which standardizes sample integrity for microarray and quantitative real-time PCR analyses with a one to 10 ranking. The method works well over a wide range of RNA concentrations, is reproducible, and is applicable to a wide range of mammalian tissues. With the new software, researchers can quantitatively assess the integrity of RNA samples before embarking on labor-intensive and costly projects.
Other key features of the software include:
- A user friendly graphical interface
- Manual peak integration
- Easy-to-find run files that enable chronological storage, sorting, and retrieval of run data with the logical and flexible, tree-view browser
- The ability to tag and label electropherograms by simply using a right click of the mouse
- Customized reports
- Results that can be exported as spreadsheets, text, and XML
- Compatibility with Microsoft Windows Vista operating system
Benefits users can expect from the Experion software include automatic calculations of size, concentration, and percent of total sample for each peak or fragment. Using the new software, users also have the ability to calculate relevant statistics such as mean, standard deviation, and %CV for measuring reproducibility. Self-training tools are available with the software. A help” function provides a “Getting Started” video as well as relevant technical bulletins.
More information about this feature is described in a downloadable technical note from (bulletin 5761) Bio-Rad's website at www.bio-rad.com.
About Bio-Rad
Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,300 people globally and had revenues approaching $1.5 billion in 2007. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, as updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.